Non-recurrent death risk monitoring model based on aGVHD biomarker

A technology for risk monitoring and modeling, applied in the field of non-recurrence mortality risk monitoring models, which can solve the problems of high dependence on detection time points, less available data, and inability to guarantee regular sample delivery.

Pending Publication Date: 2022-05-10
北京博富瑞医学检验实验室有限公司
View PDF6 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The above studies mostly focus on the relationship between aGVHD biomarker at a fixed time point and long-term clinical prognosis, and the conclusions are more dependent on the detection time point
In addition, the real-world aGVHD biomarker test cannot guarantee regular sample delivery, resulting in less available data at fixed time points, which has a certain gap with the strict enrollment criteria of patients in clinical research

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Non-recurrent death risk monitoring model based on aGVHD biomarker
  • Non-recurrent death risk monitoring model based on aGVHD biomarker
  • Non-recurrent death risk monitoring model based on aGVHD biomarker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0025] The technical scheme in the embodiment of the invention will be clearly and completely described below in combination with the attached drawings in the embodiment of the invention. Obviously, the described embodiments are only part of the embodiments of the invention, not all of the embodiments. Based on the embodiments of the invention, all other embodiments obtained by ordinary technicians in the art without making creative work belong to the protection scope of the invention.

[0026] as Figure 1-6 As shown, the invention includes four steps: aGVHD biomarker index monitoring and patient group grouping, non recurrent death model training, non recurrent death risk stratification, and dynamic monitoring of the change and trend of patient risk stratification:

[0027] 1. AGVHD biomarker index monitoring and patient group grouping. The aGVHD biomarker (sst2, reg3) at different time points of multicenter patient population was detected by Luminex platform α) Indicators. The pa...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the technical field of hematopoietic stem cell transplantation, and discloses a non-recurrent death risk monitoring model based on aGVHD biomarker, which is used for dynamically monitoring aGVHD biomarker indexes (sST2, REG3alpha) at different time points of a patient group (199 patients, non-recurrent death in one year accounts for about 12%). The method comprises the following steps: calculating a value of a distance between sST2 and REG3alpha at each detection time point within 100 days after a patient is transplanted, selecting aGVHD biomarker when the value of the distance between the sST2 and the REG3alpha at the detection time points reaches the maximum as an index of the worst condition of the patient, and establishing a model data set. According to the non-recurrent death risk monitoring model based on the aGVHD biomarker, risk grouping is carried out on patients by establishing a layering standard, the cumulative occurrence rate of non-recurrent death in 180 days is low risk (2.38%) vs medium risk (16.67%) vs high risk (52.0%), and the layering result is superior to that of existing research [5] (in initial treatment, aGVHD biomarker grouping: low risk (6%) vs medium risk (20%) vs high risk (49%)).

Description

technical field [0001] The invention relates to the technical field of hematopoietic stem cell transplantation, in particular to a non recurrent death risk monitoring model based on aGVHD biomarker. Background technology [0002] In the field of hematopoietic stem cell transplantation, complications and prognosis after transplantation have always been the most concerned issues. Due to biomarker's good diagnostic and predictive value, there have been a large number of relevant clinical studies, and a relatively standardized research process has been formed [1]. In particular, the research on aGVHD biomarker has made outstanding progress [2-6]. For example, sol á n, L. et al. Found a significant association between biomarker (ST2) on the 30th day after transplantation and non recurrent death on 720 days [2]. Ferrara, J.L., et al. Used aGVHD biomarker (sst2, reg3) on the 7th day after transplantation α) Establish a model to predict the non recurrent death of 180 days. The AUC of the...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): G16H50/30G16H10/60
CPCG16H50/30G16H10/60
Inventor 管迪李晓博苗丽丽王子琪
Owner 北京博富瑞医学检验实验室有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap